Skip to main content
Publications
Vogel A, Qin S, Kudo M, Su Y, Hudgens S, Yamashita T, Yoon JH, Fartoux L, Simon K, Lopez C, Sung M, Mody K, Ohtsuka T, Tamai T, Bennett L, Meier G, Breder V. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2021 Aug;6(8):649-58. doi: 10.1016/S2468-1253(21)00110-2
Webster-Clark M, Sturmer T, Wang T, Man K, Marinac‐Dabic D, Rothman KJ, Ellis AR, Gokhale M, Lunt M, Girman C, Glynn RJ. Using propensity scores to estimate effects of treatment initiation decisions: state of the science. Stat Med. 2021 Mar 30;40(7):1718-35. doi: 10.1002/sim.8866
Nabbout R, Auvin S, Cross JH, Guerrini R, Scheffer I, Thiele E, Chiron C, Irwin J, Mistry A, Williamson N, Grimes R, Bennett B. Cultural relevance of the global impact of Dravet Syndrome in Australia, Italy, the US and UK. Eur J Paediatr Neuro. 2017 Jun 1;21(Suppl 1):E187. doi: 10.1016/j.ejpn.2017.04.777